3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Withdrawn
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
2
Gynecologic
1
CNS
1
Breast
1
Conditions
Breast Neoplasms
15
Triple Negative Breast Neoplasms
3
Ovarian Neoplasms
2
Cardiotoxicity
2
Urogenital Neoplasms
1
Sarcoma
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Neoplastic Cells, Circulating
1
Neoplasms
1
Neoplasm Metastasis
1
Melanoma
1
Lymphoma
1
Lung Neoplasms
1
Kidney Neoplasms
1
Inflammatory Breast Neoplasms
1
Heart Diseases
1
Head and Neck Neoplasms
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma, Intraductal, Noninfiltrating
1
Breast Carcinoma In Situ
1
Breast Cancer Female
1
Brain Neoplasms
1
Interventions
pembrolizumab
29
Gemcitabine
16
Cyclophosphamide
14
Nivolumab
12
Carboplatin
12
Capecitabine
11
Trastuzumab
9
Paclitaxel
9
Magnetic Resonance Spectroscopy
8
Irinotecan
8
Bevacizumab
8
Albumin-Bound Paclitaxel
8
130-nm albumin-bound paclitaxel
8
olaparib
7
fludarabine
7
Docetaxel
7
spartalizumab
6
aldesleukin
6
Drug Therapy
6
Cisplatin
6
durvalumab
5
atezolizumab
5
Standard of Care
5
Specimen Handling
5
Oxaliplatin
5
Biopsy
5
sargramostim
4
palbociclib
4
niraparib
4
enzalutamide
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Pancreatic Neoplasms
×
Atorvastatin
×
Breast
×
Clear all
NCT02201381
2022-07-18
METRICS
Health Clinics Limited
Phase 3
Withdrawn